ORAL CONTRACEPTIVES AND THROMBOEMBOLIC DISEASE
口服避孕药和血栓栓塞性疾病
基本信息
- 批准号:6056376
- 负责人:
- 金额:$ 40.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-09-01 至 2001-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: (Adapted from Investigator's Abstract) The primary aims of the
study are to determine the following: a) the relative and attributable risk
of venous thromboembolic disease (deep venous thrombosis and pulmonary
embolism) in current users of low-dose (<50 micrograms estrogen) oral
contraceptive (OC) preparations; and b) the prevalence of the factor V
Leiden mutation in cases and controls and the relative and attributable risk
of venous thromboembolic disease associated with its presence. A
case-control study will be carried out in the defined population of women
age 15-44 years who are members of the Northern California or the Southern
California Kaiser Permanente Medical Care Program (KPMCP). Cases (n=248)
are women age 15-44 years hospitalized during a 40 month period with an
incident episode of venous thromboembolic disease in any of the 24 Kaiser
Permanente hospitals of the Northern California and Southern California
regions. For each case, 3 age-matched controls will be selected at random
from among women who are Northern California or Southern California KPMCP
members in the same year as the case's hospitalization. Cases and controls
will be interviewed to obtain detailed information about OC use and other
factors that may influence the development of venous thromboembolism. Blood
specimens will be analyzed for presence of the Factor V Leiden mutation, the
most common known hereditary risk factor for venous thrombosis.
The investigators state that the proposed study would be the first
reasonably large-scale study of the association of low-dose OC use to venous
thromboembolism performed in the United States and that it would be the
first study utilizing a population-based control group in its examination of
this association. They note that it would be performed in a setting in
which the entire study population has equal access to medical care, and in
which commonly accepted diagnostic practices are likely to be used in
determining the presence of venous thromboembolic disease. Finally, they
point out that it would provide estimates of the prevalence of the Factor V
Leiden mutation and its impact on thromboembolic disease in a racially
heterogeneous California study population.
描述:(改编自研究者摘要)
研究旨在确定以下内容:a)相对和可归因风险
静脉血栓栓塞性疾病(深静脉血栓形成和肺血栓形成)
栓塞)在目前使用低剂量(<50微克雌激素)口服
避孕(OC)制剂;和B)因子V的流行率
病例和对照中的Leiden突变以及相对和归因风险
静脉血栓栓塞性疾病的风险。 一
将在确定的妇女人群中进行病例对照研究
年龄15-44岁,是北方加州或南方的成员
加州Kaiser Permanente医疗保健计划(KPMCP)。 病例(n=248)
15-44岁的妇女在40个月期间因
24例Kaiser患者中任何一例发生静脉血栓栓塞性疾病
北方加州和南方加州的永久性医院
地区 对于每例病例,将随机选择3例年龄匹配的对照
来自北方加州或南方加州KPMCP的女性
在同一年的住院病人。 病例和对照
将接受采访,以获得有关OC使用和其他
可能影响静脉血栓栓塞发展的因素。 血液
将分析标本中是否存在凝血因子V Leiden突变,
静脉血栓形成的最常见的已知遗传危险因素。
研究人员表示,这项研究将是第一个
一项关于低剂量OC使用与静脉给药相关性的合理大规模研究
血栓栓塞在美国进行,这将是
第一项研究利用基于人口的对照组,
这个协会。 他们指出,这将是在一个环境中进行,
整个研究人群都有平等的医疗保健机会,
哪些被普遍接受的诊断实践可能被用于
确定静脉血栓栓塞性疾病的存在。 最后他们
指出,它将提供对因子V患病率的估计,
Leiden基因突变及其对一个种族血栓栓塞性疾病的影响
异质性加州研究人群。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephen Sidney其他文献
Stephen Sidney的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stephen Sidney', 18)}}的其他基金
Lifecourse CVD Risk and Midlife Cognitive Trajectories and Brain Aging: Implications for Alzheimer's and Dementia Prevention
生命全程心血管疾病风险、中年认知轨迹和大脑衰老:对阿尔茨海默病和痴呆症预防的影响
- 批准号:
10171753 - 财政年份:2019
- 资助金额:
$ 40.12万 - 项目类别:
Determinants of Midlife & Longitudinal Change in Cognitive Function: CARDIA Study
中年的决定因素
- 批准号:
9171322 - 财政年份:2014
- 资助金额:
$ 40.12万 - 项目类别:
Determinants of Midlife & Longitudinal Change in Cognitive Function: CARDIA Study
中年的决定因素
- 批准号:
8963476 - 财政年份:2014
- 资助金额:
$ 40.12万 - 项目类别:
Development of a Cardiovascular Surveillance System in the CVRN
CVRN 心血管监测系统的开发
- 批准号:
7941918 - 财政年份:2009
- 资助金额:
$ 40.12万 - 项目类别:
Development of a Cardiovascular Surveillance System in the CVRN
CVRN 心血管监测系统的开发
- 批准号:
7853075 - 财政年份:2009
- 资助金额:
$ 40.12万 - 项目类别:
20 YEAR CHANGES IN FITNESS & CARDIOVASCULAR DISEASE RISK
20年健身变化
- 批准号:
7454626 - 财政年份:2005
- 资助金额:
$ 40.12万 - 项目类别:
20 YEAR CHANGES IN FITNESS & CARDIOVASCULAR DISEASE RISK
20年健身变化
- 批准号:
6851342 - 财政年份:2005
- 资助金额:
$ 40.12万 - 项目类别:
20 YEAR CHANGES IN FITNESS & CARDIOVASCULAR DISEASE RISK
20年健身变化
- 批准号:
7174273 - 财政年份:2005
- 资助金额:
$ 40.12万 - 项目类别:
20 YEAR CHANGES IN FITNESS & CARDIOVASCULAR DISEASE RISK
20年健身变化
- 批准号:
7017724 - 财政年份:2005
- 资助金额:
$ 40.12万 - 项目类别:
20 YEAR CHANGES IN FITNESS & CARDIOVASCULAR DISEASE RISK
20年健身变化
- 批准号:
7340736 - 财政年份:2005
- 资助金额:
$ 40.12万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 40.12万 - 项目类别:
Research Grant
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 40.12万 - 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 40.12万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 40.12万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 40.12万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 40.12万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 40.12万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 40.12万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 40.12万 - 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
- 批准号:
10828252 - 财政年份:2023
- 资助金额:
$ 40.12万 - 项目类别: